Studies: Pfizer's Prevenar 13 noninferior to Merck's Pneumovax in adults, superior in some groups
This article was originally published in Scrip
Executive Summary
First-time reported results from two Phase III studies showed that Pfizer's 13-valent pneumococcal conjugate vaccine, Prevenar 13, known as Prevnar 13 in the US, was at least as immunogenic as Merck's 23-valent polysaccharide vaccine (PPSV) Pneumovax for the 12 serotypes common to both vaccines in older adults.